Paclitaxel
Targeted Mechanism: This agent selectively binds to polymerized microtubules, facilitating their stabilization and consequently disrupting normal cellular division processes.
Therapeutic Efficacy in Oncology: Demonstrates confirmed clinical effectiveness against multiple malignancies including ovarian carcinoma, breast cancer, non-small cell lung cancer, colorectal cancer, and other solid tumors.
Cell Cycle Intervention: Induces cell cycle arrest specifically during the mitotic phase, thereby inhibiting malignant cell proliferation and tumor growth.
Clinical Validation: Extensively employed in advanced cancer treatment protocols, with well-documented efficacy demonstrated through Phase II and III clinical trial investigations.
Paclitaxel is a diterpenoid compound isolated from the bark of Taxus species. This structurally complex natural product represents the sole known therapeutic agent capable of simultaneously stimulating microtubule assembly and stabilizing the resulting microtubule structures. Isotopic labeling investigations confirm that paclitaxel specifically interacts with polymerized microtubules without engaging soluble tubulin dimers.
Parameters
Melting point | 213 °C (dec.)(lit.) |
alpha | D20 -49° (methanol) |
Boiling point | 774.66°C (rough estimate) |
density | 0.2 |
refractive index | -49 ° (C=1, MeOH) |
Fp | 9℃ |
storage temp. | 2-8°C |
solubility | methanol: 50 mg/mL, clear, colorless |
form | |
pka | 11.90±0.20(Predicted) |
color | white |
Water Solubility | 0.3mg/L(37 ºC) |
λmax | 227nm(MeOH)(lit.) |
Merck | 146982 |
BRN | 1420457 |
Stability: | Stable. Incompatible with strong oxidizing agents. Combustible. |
InChIKey | RCINICONZNJXQF-MZXODVADSA-N |
LogP | 3.950 (est) |
CAS DataBase Reference | 33069-62-4(CAS DataBase Reference) |
EPA Substance Registry System | Paclitaxel (33069-62-4) |
Safety Information | |
Hazard Codes | Xn |
Risk Statements | 37/38-41-42/43-62-68-40-48-20/21/22-68/20/21/22 |
Safety Statements | 22-26-36/37/39-45 |
RIDADR | 1544 |
WGK Germany | 3 |
RTECS | DA8340700 |
F | 45951 |
HazardClass | 6.1(b) |
PackingGroup | III |
HS Code | 29329990 |
Hazardous Substances Data | 33069-62-4(Hazardous Substances Data) |
Toxicity | LD50 intraperitoneal in mouse: 128mg/kg |
Cellular administration of paclitaxel results in substantial intracellular microtubule accumulation, which disrupts multiple physiological processes—most notably by arresting cell cycle progression at the mitotic phase, thereby preventing normal cellular division. Clinical investigations (Phase II and III) have validated its primary therapeutic efficacy against ovarian and breast carcinomas, with additional demonstrated activity against diverse malignancies including non-small cell lung cancer, colorectal carcinoma, melanoma, head and neck cancers, lymphomas, and gliomas.
